Reversal of multidrug resistance by tacrolimus hydrate

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 18, Issue 10, 1996, Pages 651-658

  Wu, Jianghong ^a   Furusawa, Shinobu ^a   Nakano, Shinya ^a   Takahashi, Miki ^a   Chiba, Hiroaki ^a   Takayanagi, Motoaki ^a   Takayanagi, Yoshio ^a   Sasaki, Ken Ichi ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

cyclosporin A; cytotoxicity; epirubicin; multidrug resistance; P glycoprotein; P388 leukemia cells; tacrolimus hydrate

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; EPIRUBICIN; GLYCOPROTEIN; LACTATE DEHYDROGENASE; TACROLIMUS;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL GROWTH; CYTOTOXICITY; DRUG ACCUMULATION; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; CELL DIVISION; CYCLOSPORINE; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; IMMUNOSUPPRESSIVE AGENTS; L-LACTATE DEHYDROGENASE; LEUKEMIA P388; MICE; TACROLIMUS; TUMOR CELLS, CULTURED;

EID: 0030513527     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Senior, A.E., Al-Shawi, M.K., Urbatsch, I.L. The catalytic cycle of P-glycoprotein. FEBS Lett 1998, 377: 285-9.
2. Deffie, A.M., Alam, T., Seneviratne, C. et al. Multifactorial resistance to adriamycin: Relationship of DNA repair, glutathione transferase activity, drug efflux and P-glycoprotein in cloned cell lines of adriamycin-sensitive and resistant P388 leukemia. Cancer Res 1988, 48: 3595-602.
3. Ganapathi, R., Grabowski, D., Ford, J.M., Heiss, C., Kerrigan, D., Pommier, Y. Progressive resistance to doxorubicin in marine leukemia L1210 cells with multidrug resistance phenotype: Reductions in drug-induced topoisomerase II-mediated DNA cleavage. Cancer Commun 1989, 1: 217-24.
4. Roninson, I.B. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol 1992, 43: 95-102.
5. Morris, M.D., Graaf, D.D., Haber, M, et al. Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer 1996, 65: 613-9.
6. Coley, H.M., Twentyman, P.R., Workman. P. The efflux of anthracyclines in multidrug-resistant cell lines. Biochem Pharmacol 1993, 46: 1317-26.
7. Ganapathi, R., Herebergs, A., Grabowski, D., Ford, J. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin). Cancer Res 1993, 53: 3262-5.
8. Liebmann, J., Hahn, S.M., Cook, J.A., Lipschultz, C., Mitchell, J.B., Kaufman, D.C. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res 1993, 53: 2066-70.
9. Borel, J.F., Baumann, G., Chapman, I, et al. In vivo pharmacological effects of ciclosporin and some analogues. In: Advances in Pharmacology, Vol. 35. August, J.T., Anders, M.W., Murad, F., Coyle, J.T. (Eds.). Academic Press: San Diego 1996, 115-246.
10. Thomson, A.W. FK506 - How much potential? Immunol Today 1989, 10: 6-9.
11. Sigal, N.H., Dumont, F.J. Cyclosporin A, FK506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992, 10: 519-60.
12. Kunz, J., Hall, M.N. Cyclosporin A, FK506 and rapamycin: More than just immunosuppression. Trends Biochem Sci 1993, 18: 334-8.
13. Naito, M., Tsuge, H., Kuroko, C., Tomida, A., Tsuruo, T. Enhancement of reversing effect of Cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16. Jpn J Cancer Res 1993, 84: 489-92.
14. Yang, J.-M., Goldenberg, S., Gottesman, M.M., Hait, W.N. Characteristics of P38R/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res 1994, 54: 730-7.
15. Heo, D.S., Park, J.G., Hata, K., Day, R., Herberman, R.B., Whiteside, T.L. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 1990, 50: 3681-90.
16. Sasaki, T., Ohno, T. Cytotoxicity test on eye drop preparations by LDH release assay in human cultures cell lines. Toxicol in Vitro 1994, 5: 1113-9.
17. Bachur, N.R., Moor, A.L., Bernstein, J.G., Liu, A. Tissue distribution and disposition of daunomycin (NSC-82151) in mice: Fluorometric and isotopic methods. Cancer Chemother Rep 1970, 54: 89-94.
18. Tsuruo, T. Iida, H. Tsukagoshi, S. Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41: 1967-72.
19. Pereira, E., Teodori, E., Dei, S., Gualtieri, F., Garnier-Suillerot, A. Reversal of multidrug resistance by verapamil analogues. Biochem Pharmacol 1995, 50: 451-7.
20. Ganapathi, R., Kuo, T., Teeter, L., Grabowski, D., Ford, J. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol Pharmacol 1990, 39: 1-8.
21. Huang, C.P., DePinho, S.G., Greenberger, L.M., Arceci, R.J., Horwitz, S.B. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 1989, 264: 782-8.
22. Fujimura, T., Shibata, H., Maekawa, I. et al. Reversal of resistance to doxorubicin with cepharanthine in murine P388 leukemia cells. Jpn J Pharmacol 1990, 54: 464-7.
23. Kisara, S., Furusawa, S., Murata, R., Hikichi, N., Takayanagi, Y., Sasaki, K. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Oncol Res 1995, 3/4: 191-200.
24. Furusawa, S., Fujimura, T., Kawauchi, H., Sasaki, K., Takayanagi, Y. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells. Res Commun Pathol Pharmacol 1991, 71: 321-36.
25. Shibata, H., Maekawa, I., Furusawa, S., Kawauchi, H., Takayanagi, Y., Sasaki, K. Influences of emetine and reserpine on the antitumor activity of pirarubicin in mice bearing doxorubicin-resistant P388 leukemia. Res Commun Psychol Psychiatr Behav 1992, 17: 57-60.
26. Duncan, J.I. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK506 and rapamycin. J Invest Dermatol 1994, 102: 84-8.
27. Richter, A., Davies, D.E., Alexander, P. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin. Biochem Pharmacol 1995, 49: 367-73.
28. Sasaki, T., Kawai, K., Saijo-Kurita, K., Ohno, T. Detergent cytotoxicity: Simplified assay of cytolysis by measuring LDH activity. Toxicol In Vitro 1992, 6: 451-7.
29. Kim, W.-J., Kakehi, Y., Hirai, M. et al. Multidrug resistance-associated protein-mediated multidrug resistance modulated for cyclosporin A in a human bladder cancer cell line. Jpn J Cancer Res 1995, 86: 969-77.
30. Tamai, I., Safa, A.R. Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells. J Biol Chem 1990, 265: 16509-13.
31. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993, 268: 6077-80.